Albany - NY, Sept. 22, 2017 -- According to a new market research report published by Transparency Market Research “Heart Valve Devices Market (By Product Type: Mechanical Heart Valves {Aortic Valves, Mitral Valves}, Biological Heart Valves {Aortic Valves, Mitral Valves, Pulmonary Valves, Tricuspid Valves}, Transcatheter Heart Valves {Aortic Valves, Mitral Valves, Pulmonary Valves}; By End User: Hospitals, Ambulatory Surgical Centers): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 – 2025”, the global heart valve devices market was valued at US$ 5.8 Bn in 2016 and is estimated to reach US$ 16.2 Bn in 2025 at a CAGR of 12.4%, in terms of value, from 2017 to 2025
Extensive research and development in various aspects of design of the overall heart valve devices has led to technological advancements which is changing the paradigm of treatment of heart valve diseases. The heart valve devices increase survival rate along with improvement in the quality of life of patients. These devices are used in the replacement of diseased or the damaged natural valves of the heart, and also for valve-in-valve replacements. Heart valve devices are used for the treatment of blockage in heart valve and implantation of these devices is one of the common procedure Innovations in the transcatheter valves have led to increased adoption of advanced heart valve devices by surgeons, and is projected to rise further exponentially. Major players operating in the heart valve devices market space are mainly focusing on transcatheter mitral heart valves, whereas the startups and emerging new entrant are focused on developing innovative devices such as “bio absorbable valve” which uses in situ tissue engineering. The innovations are directed towards increasing durability of heart valves, and focusing on minimally invasive surgeries.
View Full Report at https://www.transparencymarketresearch.com/heart-valve-devices-market.html
The global heart valve devices market by type has been segmented into mechanical heart valves, biological heart valves and transcatheter heart valves. The mechanical heart valves segment is further divided into aortic valves and mitral valves. The biological heart valves are further segmented into aortic valves, mitral valves, pulmonary valves, and tricuspid valves. The transcatheter heart valves segment is classified into aortic valves, mitral valves, pulmonary valves.
Request to View Sample Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=486
In 2016, the transcatheter heart valve devices segment dominated the global heart valve devices market among the product type in terms of value. The major reasons for the dominance of the transcatheter heart valve devices segment were the rising adoption of technologically advanced products in developed regions, greater average selling prices, and significantly reduced mortality rate as compared to other segments. The transcatheter heart valves segment is likely to continue its dominance in terms of value during the forecast period. The transcatheter mitral valves are likely to have highest number of new product launches by 2025. The demand for mechanical heart valve devices continues in developing countries. The choice of prostheses in these countries is mainly dependent on two factors – lifetime of the valve with potential risk of reoperation and cost of the procedure. Thus, a large share of the population opts for mechanical heart valves particularly by local manufacturers as these products offer long life expectancy if anticoagulation is ensured.
Request to download and view full ToC - https://www.transparencymarketresearch.com/report-toc/486
The biological heart valves are likely to grow at relatively stable growth rate. However the threat of substitutes is higher for this segment as the promising new technologies such as valves made up of bio absorbable polymer scaffolds manufactured using in-situ tissue engineering, that offer therapeutic healing, are likely to be introduced in the market during the forecast period. The average selling prices of aortic biological heart valves are likely to reduce by 2025 due to rising market penetration of emerging market players resulting in increased competition, and comparatively higher selling price than that of mechanical heart valves, which are preferred in emerging countries, when cost factor is considered. In terms of end-user, the global market is divided in terms of hospitals and ambulatory surgical centers. The hospitals segments is likely to continue its dominance during the forecast owing to factors like significant market penetration, availability of skilled physicians, and highly preferred among the patients from developing countries.
Browse Our Research Blog: https://theglobalhealthnews.com/
On the basis of geography, North America is projected to continue its dominance in the global heart valve devices market due to greater adoption of technologically advanced products and techniques, and high average selling prices of heart valve devices among all regions. Europe held the second largest share of the global heart valve devices market in 2016, however Asia Pacific is anticipated to register highest CAGR in terms of value during the forecast period owing to number of factors such as significant patient pool for heart valve diseases demanding affordable care, and improving healthcare per capita spending.
Major players having presence in the global heart valve devices market includes Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, JenaValve Technology, Inc., Medtronic, Neovasc, Inc., Sorin Group (LivaNova PLC), Micro Interventional Devices, Inc., TTK HealthCare, and Lepu Medical Technology (Beijing) Co., Ltd. (Lepu Medical Group). The emerging players in the global heart valve devices market includes XELTIS, SYMETIS, Auto Tissue Berlin GmbH, and Novostia SA, among others.
About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research State Tower 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: [email protected] Website: http://www.transparencymarketresearch.com


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Instagram Outage Disrupts Thousands of U.S. Users
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 



